Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.33 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.33 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15165154 | 0.92 | ESR1 (0.38) | CYP3A4PSIP1ESR1ESR2GPR84 | |
| SCHEMBL1699282 | 0.91 | CYP3A4 (0.44) | CYP3A4PSIP1GPR84PTGDR2LTB4R | |
| SCHEMBL1699403 | 0.91 | CYP3A4 (0.46) | CYP3A4PSIP1GPR84PTGDR2LTB4R | |
| SCHEMBL1699617 | 0.91 | CYP3A4 (0.46) | CYP3A4PSIP1GPR84PTGDR2LTB4R | |
| SCHEMBL1699376 | 0.91 | CYP3A4 (0.46) | CYP3A4PSIP1GPR84PTGDR2LTB4R | |
| SCHEMBL1699344 | 0.87 | CYP3A4 (0.43) | CYP3A4PSIP1GPR84PTGDR2LTB4R | |
| SCHEMBL1699473 | 0.87 | CYP3A4 (0.43) | CYP3A4PSIP1GPR84PTGDR2LTB4R | |
| SCHEMBL1699259 | 0.85 | CYP3A4 (0.41) | CYP3A4PSIP1GPR84LTB4R | |
| SCHEMBL1699246 | 0.84 | CYP3A4 (0.49) | CYP3A4PSIP1GPR84LTB4R | |
| SCHEMBL1699278 | 0.84 | CYP3A4 (0.49) | CYP3A4PSIP1GPR84LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588450-B1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES INC (US) | 2017-05-24 | — | — | EP | disclosed |
| EP-2588450-B1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES INC (US) | 2017-05-24 | — | — | EP | disclosed |
| US-9102614-B2 | Naphth-2-ylacetic acid derivatives to treat AIDS | GILEAD SCIENCES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9102614-B2 | Naphth-2-ylacetic acid derivatives to treat AIDS | GILEAD SCIENCES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9102614-B2 | Naphth-2-ylacetic acid derivatives to treat AIDS | GILEAD SCIENCES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2588450-A1 | NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS | Gilead Sciences, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012003497-A1 | NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003497-A1 | NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | NFATC1, AADAT, ACAT1 | CYP3A4 2058/4885PSIP1 3788/4885ESR1 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.